Cancer Unfiltered

Community Health Media
  • 0.0 (0)
  • Medicine
  • Monthly

Candid podcast where leading oncologists and experts speak openly about the realities of cancer care. Through honest conversations, real-world insights, and expert perspectives, the show tackles the complex topics shaping oncology today—without the filters.

Episodes

  1. 4d ago

    Cancer Unfiltered Ep. 5: ctDNA Switch, Stop or Add with Dr. Heather Parsons & Julia Maués

    Can a simple blood test tell us when to switch, stop, or add breast cancer treatment? In Episode 5 of Cancer Unfiltered, Dr. Komal Jhaveri and Dr. Neil Iyengar are joined by Dr. Heather Parsons and patient advocate Julia Maués to explore the evolving role of circulating tumor DNA (ctDNA) in breast cancer treatment decisions. From SERENA-6 and switching therapy before radiographic progression to HER2CLIMB-05, the STOP-HER2 trial, and AFT-70 NAVIGATE, the conversation examines how ctDNA could help guide treatment escalation, de-escalation, and personalized care. Beyond the data, they tackle the unanswered questions: When should clinicians act on molecular findings? Can some patients safely stop treatment? And how do we balance promising innovations with treatment burden, toxicity, and patient preferences? ▶️ Watch on YouTube - https://youtu.be/Mh2uNBGrRLI 🎧 Listen on Spotify, Apple Podcasts, Amazon Music, CastBox & iHeartRadio: https://linkin.bio/cancerunfiltered Cancer Unfiltered is part of the Community Health Media Podcast Network, where meaningful conversations help patients, caregivers, advocates, and healthcare professionals learn from one another, one story at a time. #CancerUnfiltered #ctDNA #BreastCancer #SERENA6 #STOPHER2 #NAVIGATETrial #MetastaticBreastCancer #PrecisionOncology #MedicalOncology #CommunityHealthMedia

    Cancer Unfiltered Ep. 5: ctDNA Switch, Stop or Add with Dr. Heather Parsons & Julia Maués

  2. Aug 24

    Cancer Unfiltered Ep. 4: VIKTORIA-1 in HR+ mBC with Drs. Komal Jhaveri & Neil Iyengar

    One trial. One therapy. Countless clinical questions. In Episode 4 of Cancer Unfiltered, Dr. Komal Jhaveri and Dr. Neil Iyengar take a deep dive into the VIKTORIA-1 trial and discuss how gedatolisib may reshape treatment for patients with HR-positive, HER2-negative metastatic breast cancer. Beyond reviewing the data, they explore where this regimen fits in clinical practice, who may benefit most, concerns surrounding toxicity and treatment burden, and how VIKTORIA-1 compares with other rapidly emerging therapies in this evolving treatment landscape. Topics discussed: VIKTORIA-1 trial design and key efficacy results Gedatolisib triplet vs. doublet therapy Managing HR-positive, HER2-negative metastatic breast cancer Intravenous therapy vs. oral treatment options Stomatitis and other treatment-related toxicities Patient selection and co-mutations How PAM pathway inhibition may overcome resistance Sequencing endocrine therapies after progression Emerging trials including FOURLIGHT-1 and selective CDK4 inhibitors The future of targeted therapy in metastatic breast cancer Recorded prior to the July 2026 FDA approval of gedatolisib (Revtorpyk) with fulvestrant, ± palbociclib, for HR-positive, HER2-negative advanced breast cancer without a detectable PIK3CA mutation after progression on prior endocrine therapy. ▶️ Watch on YouTube - https://youtu.be/43BVZ9nL424 🎧 Listen on Spotify, Apple Podcasts, Amazon Music, CastBox & iHeartRadio - https://linkin.bio/cancerunfilteredpodcast/ #CancerUnfiltered #VIKTORIA1 #Gedatolisib #HRPositive #MetastaticBreastCancer #MedicalOncology #BreastCancer #PI3K #PIK3CA #TargetedTherapy #CommunityHealthMedia

    Cancer Unfiltered Ep. 4: VIKTORIA-1 in HR+ mBC with Drs. Komal Jhaveri & Neil Iyengar

  3. Jul 30

    Cancer Unfiltered Ep. 3: New FDA Approvals, Practice-Changing Trials & What's Next in Breast Cancer

    Breast cancer treatment is changing at an unprecedented pace. In Episode 3 of Cancer Unfiltered, Dr. Komal Jhaveri and Dr. Neil Iyengar discuss the latest FDA approvals, landmark clinical trials, and emerging treatment strategies that are reshaping care across HR-positive, HER2-positive, and triple-negative breast cancer. From practice-changing DESTINY data to the expanding role of antibody-drug conjugates, this episode breaks down what the latest evidence means for treatment decisions today. Topics discussed: • Six new FDA approvals across all major breast cancer subtypes • Vepdegestrant and the VERITAC-2 trial for ESR1-mutant HR-positive breast cancer • DESTINY-Breast11, DESTINY-Breast05, and DESTINY-Breast09: key findings and clinical impact • The growing role of antibody-drug conjugates (ADCs) in first-line metastatic triple-negative breast cancer • Treatment sequencing and how new approvals are changing clinical decision-making • Which HER2-positive patients may benefit most from the DESTINY-Breast09 approach • Brain metastases, PIK3CA mutations, and selecting therapy for high-risk patients • Giredestrant and the lidERA trial: improving endocrine therapy options • VIKTORIA-1 and emerging therapies targeting the PI3K/AKT/mTOR (PAM) pathway • The future of breast cancer treatment and practice-changing data to watch Whether you're an oncologist, advanced practice provider, researcher, or healthcare professional, this episode offers practical insights into the rapidly evolving breast cancer treatment landscape and what these developments mean for patient care. ▶️ Watch on YouTube - https://youtu.be/m0l8feuG6Y8 🎧 Listen on Spotify, Apple Podcasts, Amazon Music, CastBox, & iHeartRadio - https://linkin.bio/cancerunfiltered Cancer Unfiltered is part of the Community Health Media Podcast Network, where meaningful conversations help patients, caregivers, advocates, and healthcare professionals learn from one another, one story at a time. #CancerUnfiltered #BreastCancer #Oncology #MedicalOncology #FDAApprovals #DESTINYBreast11 #DESTINYBreast05 #Vepdegestrant #TripleNegativeBreastCancer #HER2Positive #CancerPodcast #CommunityHealthMedia

    Cancer Unfiltered Ep. 3: New FDA Approvals, Practice-Changing Trials & What's Next in Breast Cancer

  4. Jun 30

    Cancer Unfiltered Ep. 2: ESMO Breast 2026 with Drs. Komal Jhaveri & Neil Iyengar

    The conversation continues. In Episode 2 of Cancer Unfiltered, Dr. Komal Jhaveri and Dr. Neil Iyengar break down the biggest updates from ESMO Breast 2026, including DESTINY-Breast11, SERENA-6, ctDNA monitoring, exercise and metabolic health, emerging novel therapies, and the future of ER-positive breast cancer treatment. From controversial questions surrounding molecular progression to exciting new therapies in development, this episode explores where breast cancer care is heading next. If Episode 1 introduced the conversation, Episode 2 takes it even further. ▶️ Watch on YouTube - https://youtu.be/Bq6HCsyn7b4 🎧 Listen on Spotify, Apple Podcasts, Amazon Music, CastBox, & iHeartRadio - https://linkin.bio/cancerunfiltered Cancer Unfiltered is part of the Community Health Media Podcast Network, where meaningful conversations help patients, caregivers, advocates, and healthcare professionals learn from one another, one story at a time. #CancerUnfiltered #ESMOBreast2026 #BreastCancer #Oncology #MedicalOncology #ERPositive #HER2Positive #ctDNA #SERENA6 #CancerPodcast #HealthcareEducation #CommunityHealthMedia

    Cancer Unfiltered Ep. 2: ESMO Breast 2026 with Drs. Komal Jhaveri & Neil Iyengar

  5. Jun 30 ·  Bonus

    Cancer Unfiltered Bonus: How Drs. Jhaveri & Iyengar See the Future of Breast Cancer

    Before the data drops, the hot takes, and the controversies, there was Miami. In this special bonus episode, Dr. Komal Jhaveri and Dr. Neil Iyengar introduce Cancer Unfiltered and discuss the biggest questions shaping breast oncology today. From oral SERDs and overcoming ESR1 mutations to the monotherapy vs. combination debate, ADC sequencing, first-line triple-negative breast cancer strategies, and the real-world application of precision medicine, this conversation lays the foundation for everything that follows. This is where Cancer Unfiltered began. ▶️ Watch on YouTube - https://youtu.be/sMbRsnGNamQ 🎧 Listen on Spotify, Apple Podcasts, Amazon Music, CastBox, & iHeartRadio - https://linkin.bio/cancerunfiltered Cancer Unfiltered is part of the Community Health Media Podcast Network, where meaningful conversations help patients, caregivers, advocates, and healthcare professionals learn from one another, one story at a time. #CancerUnfiltered #BreastCancer #Oncology #MedicalOncology #ESR1 #OralSERD #ADC #TripleNegativeBreastCancer #MetastaticBreastCancer #CancerPodcast #CommunityHealthMedia

    Cancer Unfiltered Bonus: How Drs. Jhaveri & Iyengar See the Future of Breast Cancer

  6. May 26

    Cancer Unfiltered Debut: Dr. Komal Jhaveri & Dr. Neil Iyengar on Breast Cancer

    The conversations oncology has been waiting for are finally here. Welcome to the very first episode of Cancer Unfiltered with Dr. Komal Jhaveri & Dr. Neil Iyengar. From SERDs and ctDNA to resistance mechanisms, NGS profiling, T-DXd, and the future of metastatic breast cancer treatment, nothing is off limits. Real conversations. Real controversies. Real clinical insight. This is oncology without the filters. FULL EPISODE OUT NOW! ▶️ Watch on YouTube - https://youtu.be/7cIohpPZoIo 🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox and Amazon Music - https://linkin.bio/cancerunfiltered Cancer Unfiltered is part of the Community Health Media Podcast Network, where meaningful conversations help patients, caregivers, advocates, and healthcare professionals learn from one another, one story at a time. #CancerUnfiltered #BreastCancer #Oncology #MedicalOncology #MetastaticBreastCancer #HER2Positive #ERPositive #TDXd #NGS #ctDNA #SERD #CancerPodcast #HealthcareEducation #CommunityHealthMedia

    Cancer Unfiltered Debut: Dr. Komal Jhaveri & Dr. Neil Iyengar on Breast Cancer

  7. May 26

    Cancer Unfiltered Ep. 1: Shifting Paradigms in Breast Cancer with Drs. Komal Jhaveri & Neil Iyengar

    What happens when two leading breast oncologists sit down for an unfiltered conversation on the biggest breakthroughs, controversies, and real-world challenges in breast cancer today? In Episode 1 of Cancer Unfiltered, Dr. Komal Jhaveri and Dr. Neil Iyengar break down the latest data in metastatic breast cancer, including SERENA-6, PATINA, HER2CLIMB-05, DB-09, oral SERDs, ctDNA monitoring, and the evolving future of personalized treatment strategies. From hot takes on HER2-positive disease to real patient cases that highlight the complexity of ER-positive metastatic breast cancer, this episode dives into the clinical decisions shaping breast oncology today. ▶️ Watch on YouTube - https://youtu.be/7cIohpPZoIo 🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox and Amazon Music - https://linkin.bio/cancerunfiltered Cancer Unfiltered is part of the Community Health Media Podcast Network, where meaningful conversations help patients, caregivers, advocates, and healthcare professionals learn from one another, one story at a time. #CancerUnfiltered #BreastCancer #Oncology #MedicalOncology #HER2Positive #ERPositive #MetastaticBreastCancer #ESR1 #ctDNA #OralSERD #BreastCancerResearch #ASCO #CancerPodcast #HealthcareEducation #CommunityHealthMedia

    Cancer Unfiltered Ep. 1: Shifting Paradigms in Breast Cancer with Drs. Komal Jhaveri & Neil Iyengar
  • 1 Trailer
    6 Episodes

Trailer

About

Candid podcast where leading oncologists and experts speak openly about the realities of cancer care. Through honest conversations, real-world insights, and expert perspectives, the show tackles the complex topics shaping oncology today—without the filters.

Information

  • Creator
    Community Health Media
  • Years Active
    2026
  • Episodes
    7
  • Rating
    Clean
  • Copyright
    © Community Health Media
  • Show Website
    Cancer Unfiltered